Acknowledgements
The authors thank the study participants, their families, and investigators involved in the clinical trials. Medical writing support, under the direction of the authors, was provided by Richard Knight, Ph.D., and Jane Davies of CMC Connect, a division of IPG Health Medical Communications, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175(9):1298–1304) and was funded by AstraZeneca. Nirsevimab is being developed and commercialized in partnership between AstraZeneca and Sanofi.